Regeneron Pharmaceuticals (REGN)
Stock-Based Compensation
$243.00M
Quarterly · Period ending: · USD
REGN Stock-Based Compensation
Latest reported$243.00Mperiod ending
Latest reported$243.00Mperiod ending
REGN Quarterly Stock-Based Comp ($0.00 → $243.00M)
Quarterly stock-based compensation
High-resolution chart · PNG
REGN stock-based compensation history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 243,000,000 | |
| 257,400,000 | |
| 249,300,000 | |
| 237,000,000 | |
| 251,700,000 | |
| 255,700,000 | |
| 304,400,000 | |
| 225,100,000 | |
| 223,200,000 | |
| 230,100,000 | |
| 240,400,000 | |
| 203,900,000 | |
| 202,000,000 | |
| 238,700,000 | |
| 232,000,000 | |
| 166,300,000 | |
| 159,800,000 | |
| 166,900,000 | |
| 188,400,000 | |
| 136,900,000 | |
| 145,500,000 | |
| 130,900,000 | |
| 121,500,000 | |
| 101,200,000 | |
| 103,500,000 | |
| 105,800,000 | |
| 133,500,000 | |
| 117,100,000 | |
| 105,800,000 | |
| 107,900,000 | |
| 126,748,000 | |
| 111,435,000 | |
| 106,795,000 | |
| 82,422,000 | |
| 127,133,000 | |
| 125,097,000 | |
| 121,258,000 | |
| 133,789,000 | |
| 154,558,000 | |
| 131,379,000 | |
| 131,691,000 | |
| 142,250,000 | |
| 158,392,000 | |
| 102,641,000 | |
| 94,257,000 | |
| 103,759,000 | |
| 81,454,000 | |
| 73,864,000 | |
| 70,512,000 | |
| 81,408,000 | |
| 55,182,000 | |
| 45,744,000 | |
| 44,443,000 | |
| 53,030,000 | |
| 51,307,000 | |
| 20,500,000 | |
| 19,606,000 | |
| 23,244,000 | |
| 15,533,000 | |
| 13,364,000 | |
| 12,396,000 | |
| 14,801,000 | |
| 13,566,000 | |
| 8,790,000 | |
| 8,707,000 | |
| 8,834,000 | |
| 8,657,000 | |
| 7,508,000 | |
| 7,440,000 | |
| 7,654,000 | |
| 0 | |
| 0 | |
| 8,214,000 | |
| 8,286,000 | |
| 0 | |
| 0 | |
| 0 | |
| 6,585,000 | |
| 0 | |
| 4,632,000 | |
| 4,700,000 | |
| 4,079,000 | |
| 0 | |
| 0 | |
| 0 | |
| 5,881,000 | |
| 0 | |
| 0 | |
| 0 | |
| 671,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |